Eurocine Vaccines
Fogdevreten 2
Karolinska Institutet Science Park
Solna
SE-171 65
Website: https://www.eurocine-vaccines.com/
Email: info@eurocine-vaccines.com
About Eurocine Vaccines
Eurocine Vaccines is a publicly listed, clinical-stage company developing nasal vaccines that meet important medical needs. The vaccines are developed up to proof of concept (clinical phase I/II) and licensed to partners for further development and commercialization.YEAR FOUNDED:
1999
LEADERSHIP:
Founder: Ulf Schr?der
CEO: Hans Arwidsson
CSO: Anna-Karin Maltais
CLINICAL TRIAL:
Please click here for clinical trial information.
7 articles about Eurocine Vaccines
-
Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate
12/20/2022
As communicated earlier, Eurocine Vaccines is conducting preclinical trials to evaluate the mRNA and protein technology platforms for its therapeutic Herpes simplex virus type 2, HSV-2, vaccine candidates.
-
Eurocine Vaccines extends its product portfolio with a diagnostic test of chlamydia through a widened agreement with Spixia Biotechnology
8/25/2021
Chlamydia is a sexually transmitted bacterial disease that often leads to involuntary infertility in women.
-
Eurocine Vaccines´ Adjuvant Technology Endocine™ is evaluated with a vaccine candidate against COVID-19
5/19/2021
Eurocine Vaccines has signed a Material Transfer Agreement regarding the evaluation of Endocine™ together with a vaccine candidate against COVID-19
-
Eurocine Vaccines Challenges the Flu
12/14/2017
While Australia has faced one of the harshest influenza seasons of decades, Eurocine Vaccines prepares for the next phase of development, a second clinical study with its first vaccine candidate Immunose FLU, to fight the same.
-
Eurocine Vaccines Strengthens The Organization For Further Development
4/7/2017
-
Eurocine Vaccines Expects Clinical Results June/July 2017
4/6/2017
-
Eurocine Vaccines Announces Initiation Of Clinical Study Of The Nasal Influenza Vaccine Candidate Immunose FLU
10/25/2016